Boston Scientific Announces Additional Investment and Right to Acquire MValve Technologies


Investment continues alliance for percutaneous mitral valve replacement established in 2012



MARLBOROUGH, Mass. and HERZLIYA, Israel - Boston Scientific Corporation (NYSE: BSX) today announced that it has closed on an additional round of financing with MValve Technologies Ltd., a developer of a percutaneous mitral valve replacement system, designed to work with the Boston Scientific LOTUS™ Valve, creating a unique mitral regurgitation (MR) treatment solution. Boston Scientific has provided the company with funding since 2012 and has an exclusive option to acquire MValve.



MValve Technologies plans to utilize the new financing, in part, to fund a first-in-human clinical trial for the MValve docking system for transcatheter mitral valve replacement (TMVR) in patients with mitral regurgitation. The approach, in which the Boston Scientific Lotus Valve is deployed inside the MValve docking system, is designed to enable the treatment of mitral regurgitation in a broad range of patients, and to improve long-term clinical outcomes in this patient population. Both the dock and valve can be repositioned and recaptured, enabling precise valve placement and physician confidence prior to releasing.



Mitral regurgitation is the most common type of heart valve disorder and occurs when the mitral valve does not close properly, causing an abnormal reversal of blood to flow from the left ventricle into the left atrium.



"The TMVR segment represents another significant growth opportunity as we continue to build our Structural Heart portfolio," said Kevin Ballinger, senior vice president and president, Interventional Cardiology, Boston Scientific. "This round of financing will support the development of the MValve technology in anticipation of a first-in-human clinical trial, and we are pleased to be continuing our collaboration."



"MValve is proud of our truly novel technology, and we look forward to continued development of this unique mitral system - a system that we anticipate will finally provide physicians with a transformative solution and offer patients the appropriate treatment they deserve," said Dr. Maurice Buchbinder, interventional cardiologist, founder and medical director, MValve Technologies.



The MValve docking system is not available for sale.



About the Lotus Valve System

The Lotus Aortic Valve System is a differentiated second-generation valve replacement technology, consisting of a pre-loaded, stent-mounted tissue valve prosthesis and catheter delivery system for guidance and percutaneous placement of the valve. The low-profile delivery system is designed to enable predictable and precise placement associated with early valve function, as well as bi-directional atraumatic repositioning and retrieval at any time prior to release of the aortic valve implant. The device also features a unique Adaptive Seal™ designed to minimize the incidence of paravalvular regurgitation.



In the U.S., the Lotus Valve System is an investigational device and not available for sale. It is CE marked in the European Union.



About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit us at www.bostonscientific.com.



About MValve

MValve Technologies Ltd. is a privately held corporation founded in 2011, with lead investment from Boston Scientific corporation. MValve is dedicated to the development of novel and minimally invasive technologies for transcatheter valve replacement. The company operates from Herezeliya, Israel and San Diego.



CONTACTS



Media:

Tom Keppeler

508-683-6585 (office)

Media Relations

Boston Scientific Corporation

thomas.keppeler@bsci.com



Investors:

Susie Lisa, CFA

508- 683-5565 (office)

Investor Relations

Boston Scientific Corporation

investor_relations@bsci.com



SOURCE Boston Scientific Corporation



Web Site: http://www.bostonscientific.com

More from Sensors, Monitors & Transducers

All Topics